- Home
- DX vs TNGX Comparison
DX vs TNGX Comparison
Compare DX & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DX | TNGX |
|---|---|---|
| Founded | 1987 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DX | TNGX |
|---|---|---|
| Price | $14.03 | $9.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $13.33 | $12.50 |
| AVG Volume (30 Days) | ★ 4.9M | 2.9M |
| Earning Date | 10-20-2025 | 11-04-2025 |
| Dividend Yield | ★ 14.54% | N/A |
| EPS Growth | ★ 35.65 | N/A |
| EPS | ★ 1.66 | N/A |
| Revenue | ★ $230,447,000.00 | $66,501,000.00 |
| Revenue This Year | N/A | $53.01 |
| Revenue Next Year | $134.14 | N/A |
| P/E Ratio | $8.46 | ★ N/A |
| Revenue Growth | ★ 87.09 | 53.29 |
| 52 Week Low | $10.79 | $1.03 |
| 52 Week High | $14.52 | $11.20 |
Technical Indicators
Market Signals| Indicator | DX | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 67.11 | 55.38 |
| Support Level | $13.80 | $9.46 |
| Resistance Level | $14.06 | $10.22 |
| Average True Range (ATR) | 0.18 | 0.69 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 97.09 | 54.99 |
Price Performance
Historical ComparisonAbout DX Dynex Capital Inc.
Dynex Capital Inc is an internally managed mortgage real estate investment trust, which invests in mortgage-backed securities. The company invests in residential and commercial mortgage-backed securities. Its objective is to provide attractive risk-adjusted returns to shareholders over the long term that are reflective of a leveraged, high quality fixed income portfolio with a focus on capital preservation. Its investments consist principally of Agency mortgage-backed securities including, residential MBS and commercial MBS.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.